Charles River and Lundbeck Collaborate to Harness AI-Powered Logica for Novel Neurological Drug Discovery

Charles River Laboratories International, Inc. announced an agreement with H. Lundbeck A/S (Lundbeck) to utilize Logica to progress critical brain disease research.

“We are excited to partner with Lundbeck as they work toward the discovery of novel treatments for neurodegenerative disease,” said Professor Julie Frearson, Ph.D., Senior Vice President and Chief Scientific Officer, Charles River. “Logica’s integrated, AI-augmented process allows us to be an agile partner, and combined with Lundbeck’s industry-leading neurology expertise, we look forward to a successful collaboration.”

Logica is an Artificial Intelligence (AI) powered end-to-end drug discovery solution that translates biological insights into optimized preclinical candidates by leveraging the integration of Valo Health’s AI-powered Opal Computational Platform and Charles River’s leading expertise in drug discovery and preclinical development. Through the agreement, Lundbeck will deploy Logica with the aim of creating optimized small molecules that lead to novel therapies for neurological research.

“To make a significant impact on neurological diseases today, you need to be able to work on unprecedented molecular targets with causal biology,” said Tarek Samad, Senior Vice President and Head of Global Research at Lundbeck. “Partnering with Logica will allow us to use a unique tool set, including AI-driven approaches, to overcome drug design challenges which often slow down the translation of promising targets into drug candidates.”